What did @gabrielakratz_ actually say?
Honestly? Almost nothing, verbally. The transcript is just "I'm not the one" repeated four times, which appears to be audio from a trending TikTok sound rather than any direct claim about tirzepatide, weight loss, or her experience. The video's claims are entirely visual: a before-and-after body transformation, tagged with #mounjaro, #antesedepois (before and after), and #emagrecimento (weight loss). The caption says "my body evolution in 2 months." So we're fact-checking a visual argument, not a spoken one.
That matters. Before-and-after content is one of the most persuasive formats on social media, and it does the work of a hundred spoken claims without being accountable for any of them. Viewers fill in the blanks themselves: Mounjaro caused this, this is typical, this is safe, this could happen to me.
Does the science back up a visible 2-month transformation on tirzepatide?
Yes, tirzepatide does produce meaningful weight loss, and two months is enough time to see it. But the scale of results varies significantly between individuals, and what you see in a before-and-after is almost never the full picture.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on the highest dose of tirzepatide (15 mg) lost an average of 20.9% of body weight over 72 weeks. At 8 weeks, early responders were already seeing measurable changes, but average loss at that point was far more modest. A 2023 analysis by Frías et al. in Diabetes Care confirmed that individual response in the first two months ranges from minimal to dramatic depending on baseline metabolic health, starting dose, dietary habits, and adherence.
Lighting, posture, clothing, and camera angle in before-and-after photos can exaggerate or minimize change by an amount that is genuinely hard to estimate. None of that means the transformation shown is fake. It means it is not a data point you can apply to yourself.
What did she get wrong, or right?
She didn't make any explicit medical claims, so there's nothing to directly reject. That's worth acknowledging. She didn't say tirzepatide is safe for everyone, didn't suggest a dose, didn't claim compounded versions are equivalent to brand-name Mounjaro. By saying nothing, she avoided the most common errors in this content category.
What she did do is participate in a content format that systematically implies several things: that 2-month results are reliable and replicable, that the drug alone explains the transformation, and that dramatic physical change is the primary reason to care about GLP-1 receptor agonists. These are not her words, but they are what the format communicates.
The absence of any mention of side effects, the clinical context for use, or what happened in the first weeks (nausea and gastrointestinal distress affect a significant portion of users early on) is a real gap. Not a lie. A gap.
What should you actually know about tirzepatide results?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is why its weight loss data outperforms older GLP-1 drugs like semaglutide in head-to-head analysis. The SURMOUNT-2 trial (Garvey et al., 2023, The Lancet) showed 15.7% average weight loss over 72 weeks in adults with obesity and type 2 diabetes. These are averages. Some people lose significantly more. Some lose much less. About 5-10% of participants in major trials are classified as non-responders.
Side effects in early weeks include:
- Nausea (reported by 30-45% of users in the first month)
- Vomiting and diarrhea, especially as dose escalates
- Delayed gastric emptying, which affects medication timing for other drugs
Before-and-after content on social media disproportionately features people who responded well and felt good enough to post about it. The people who stopped because of side effects, who didn't see results, or who regained weight after stopping are not showing up in your algorithm. That is a real selection bias problem, and it shapes public expectations in a way that sets people up for disappointment or unnecessary risk.
The bottom line on this video
This is an optimistic, largely silent piece of content that shows one person's real result on Mounjaro over two months. It's not misinformation in the traditional sense. But before-and-after videos without clinical context function as advertising, even when that's not the intent. The hashtag alone puts it in front of hundreds of thousands of people evaluating whether to start, continue, or pressure their doctor for a prescription.
If you're considering tirzepatide, the evidence base is genuinely strong. But it is a medication with a specific prescribing context, a side effect profile that the first two months will test, and a weight regain pattern (Wilding et al., 2022, Diabetes Care) that makes stopping it without lifestyle infrastructure a real clinical risk. One person's 2-month glow-up doesn't tell you any of that.